Months after a significant M&A deal with AstraZeneca, EsoBiotec has unveiled initial, promising clinical data for its in vivo T-cell editing therapy, ESO-T01, in patients with multiple myeloma. Results from an ongoing Phase 1 trial in Wuhan, China, show that all four treated patients with relapsed or refractory multiple myeloma responded to the therapy, with two patients achieving complete resolution of their cancer.
ESO-T01 is designed to be a game-changer in cell therapy. Unlike traditional CAR-T approaches that require T cells to be modified outside the body, EsoBiotec uses lentivirus vectors to deliver mRNA directly into T cells within the patient’s body. This reprograms the immune cells to target B-cell maturation antigen (BCMA), a protein often overexpressed in multiple myeloma cells.
All four patients received a single infusion of ESO-T01. While they experienced adverse events common with cell therapies, such as acute inflammatory reactions (chills, fevers, low blood pressure) and cytokine release syndrome (CRS), and one case of immune effector cell-associated neurotoxicity syndrome (ICANS), the efficacy signals are compelling.
Key Efficacy Highlights:
- One patient’s cancerous lesions and malignant blood cells in the bone marrow completely disappeared by day 28.
- Another patient achieved complete resolution by two months post-treatment.
- The remaining two patients showed partial responses, with shrinking lesions and reduced cancer cells.
- The therapy notably appeared to eradicate extramedullary disease (myeloma spread outside the bone marrow).
These early results follow the initial single-patient data presented at the J.P. Morgan Healthcare Conference in January, which sparked AstraZeneca’s acquisition deal worth up to $1 billion. While researchers note that a larger cohort and longer follow-up are needed for definitive conclusions, these initial findings underscore the potential of EsoBiotec’s in vivo cell editing platform to offer a novel and impactful treatment option for multiple myeloma.
Source:
https://www.fiercebiotech.com/biotech/cell-therapy-biotech-shares-first-clinical-data-vivo-car-t-attracted-1b-astrazeneca?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=7621D2649190G5B ; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01030-X/fulltext
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
